Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

doi:10.1016/j.clgc.2026.102638

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Clinical genitourinary cancer - 1 Oct 2026

Mercinelli Chiara, Basile Giuseppe, Pastorino Giovanni L, Cigliola Antonio, Maiorano Brigida A, Tateo Valentina, Piacentini Michela, Serafin Debora, Guandalini Gualtiero, Lacava Roberta, Latini Gaia, Colecchia Maurizio, Briganti Alberto, Moschini Marco, Montorsi Francesco, Pavlick Dean, Ross Jeffrey S, Necchi Andrea

Abstract excerpt

INTRODUCTION: Immune checkpoint inhibitors (ICI) have demonstrated meaningful activity as neoadjuvant therapy in muscle-invasive bladder cancer (MIBC). Identifying patients most likely to respond to ICI-based neoadjuvant strategies remains an unmet need. MATERIALS AND METHODS: Tumor mutational burden (TMB) from baseline transurethral resection of bladder (TURB) tumor samples of MIBC patients treated with...

Read the complete abstract on PubMed

Topics

Aged
Female
Humans
Male
Middle Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Biomarkers, Tumor

Cystectomy

Immune Checkpoint Inhibitors

Mutation

Neoadjuvant Therapy

Pathologic Complete Response

Prognosis

Transurethral Resection of Bladder

Treatment Outcome

Tumor Burden

Urinary Bladder Neoplasms

Clinical Trials, Phase II as Topic

Source

Open in PubMed

Identifiers

PMID: 42632232
DOI: 10.1016/j.clgc.2026.102638

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.PMID 42632232Read ↗

Tumor Immune Infiltration as a Predictor of Response to Neoadjuvant Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: An Integrative TCGA AnalysisSemantic proximity Read ↗

Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Semantic proximity Read ↗

Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancerSemantic proximity Read ↗

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis.Semantic proximity Read ↗

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity Read ↗

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity Read ↗

Molecular subtyping of invasive bladder cancer: time to divide and rule?Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.